Ohad Karnieli

1.3k total citations
13 papers, 785 citations indexed

About

Ohad Karnieli is a scholar working on Molecular Biology, Biomedical Engineering and Physiology. According to data from OpenAlex, Ohad Karnieli has authored 13 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Biomedical Engineering and 4 papers in Physiology. Recurrent topics in Ohad Karnieli's work include Pluripotent Stem Cells Research (6 papers), Biomedical Ethics and Regulation (4 papers) and 3D Printing in Biomedical Research (4 papers). Ohad Karnieli is often cited by papers focused on Pluripotent Stem Cells Research (6 papers), Biomedical Ethics and Regulation (4 papers) and 3D Printing in Biomedical Research (4 papers). Ohad Karnieli collaborates with scholars based in United States, Israel and Singapore. Ohad Karnieli's co-authors include Shimon Efrat, Shlomo Bulvik, Steve Oh, Michal Zalzman, Norman Fleischer, Baljit S. Sappal, Sanjeev Gupta, Ranjit K. Giri, Mark Α. Zern and Knut Niß and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Stem Cells and Stem Cells Translational Medicine.

In The Last Decade

Ohad Karnieli

13 papers receiving 757 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ohad Karnieli United States 10 483 353 227 227 147 13 785
Smruti M. Phadnis India 10 308 0.6× 436 1.2× 182 0.8× 95 0.4× 57 0.4× 12 665
Alexander Stoff Germany 15 229 0.5× 228 0.6× 173 0.8× 214 0.9× 62 0.4× 25 693
Weibiao Huang United States 13 98 0.2× 285 0.8× 84 0.4× 102 0.4× 48 0.3× 18 643
María Álvarez‐Viejo Spain 11 192 0.4× 152 0.4× 158 0.7× 59 0.3× 41 0.3× 18 493
Takehiko Yamazaki Japan 12 98 0.2× 307 0.9× 211 0.9× 104 0.5× 20 0.1× 20 813
Sophie Vériter Belgium 10 298 0.6× 68 0.2× 192 0.8× 82 0.4× 95 0.6× 13 495
John M. Centanni United States 11 170 0.4× 203 0.6× 174 0.8× 47 0.2× 16 0.1× 16 545
Ichiro Masaki Japan 8 149 0.3× 344 1.0× 60 0.3× 175 0.8× 22 0.1× 10 623
Li Deng China 15 236 0.5× 193 0.5× 313 1.4× 32 0.1× 17 0.1× 37 693
Joseph Michaels United States 10 139 0.3× 128 0.4× 88 0.4× 71 0.3× 66 0.4× 12 499

Countries citing papers authored by Ohad Karnieli

Since Specialization
Citations

This map shows the geographic impact of Ohad Karnieli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ohad Karnieli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ohad Karnieli more than expected).

Fields of papers citing papers by Ohad Karnieli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ohad Karnieli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ohad Karnieli. The network helps show where Ohad Karnieli may publish in the future.

Co-authorship network of co-authors of Ohad Karnieli

This figure shows the co-authorship network connecting the top 25 collaborators of Ohad Karnieli. A scholar is included among the top collaborators of Ohad Karnieli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ohad Karnieli. Ohad Karnieli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Kim, Jung‐Hyun, et al.. (2022). Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies. npj Regenerative Medicine. 7(1). 54–54. 10 indexed citations
2.
Karnieli, Ohad, et al.. (2019). ISCT survey reponses to process and product development committee's cost-of-goods questionnaire. Cytotherapy. 21(5). e11–e11. 1 indexed citations
3.
Karnieli, Ohad, Julie Allickson, Nan Zhang, et al.. (2016). A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy. 19(2). 155–169. 151 indexed citations
4.
Clarke, Dominic, et al.. (2016). Managing particulates in cell therapy: Guidance for best practice. Cytotherapy. 18(9). 1063–1076. 13 indexed citations
5.
Abraham, Eytan, et al.. (2015). Critical elements in the development of cell therapy potency assays for ischemic conditions. Cytotherapy. 17(7). 817–831. 9 indexed citations
6.
Campbell, Andrew M., Jon A. Rowley, Knut Niß, et al.. (2015). Concise Review: Process Development Considerations for Cell Therapy. Stem Cells Translational Medicine. 4(10). 1155–1163. 101 indexed citations
7.
8.
Eaker, Shannon, Myriam Armant, Harvey Brandwein, et al.. (2013). Concise Review: Guidance in Developing Commercializable Autologous/Patient-Specific Cell Therapy Manufacturing. Stem Cells Translational Medicine. 2(11). 871–883. 45 indexed citations
9.
Clarke, Dominic, Jon A. Rowley, Michael McCaman, et al.. (2012). Managing particulates in cellular therapy. Cytotherapy. 14(9). 1032–1040. 10 indexed citations
10.
Yavelsky, Victoria, et al.. (2008). Enhancement of hybridoma formation, clonability and cell proliferation in a nanoparticle-doped aqueous environment. BMC Biotechnology. 8(1). 3–3. 5 indexed citations
11.
Kuzi, Sharon, et al.. (2008). Canine Procalcitonin Messenger RNA Expression. Journal of Veterinary Diagnostic Investigation. 20(5). 629–633. 18 indexed citations
12.
Karnieli, Ohad, et al.. (2007). Generation of Insulin-Producing Cells from Human Bone Marrow Mesenchymal Stem Cells by Genetic Manipulation. Stem Cells. 25(11). 2837–2844. 215 indexed citations
13.
Zalzman, Michal, Sanjeev Gupta, Ranjit K. Giri, et al.. (2003). Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells. Proceedings of the National Academy of Sciences. 100(12). 7253–7258. 202 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Smruti M. Phadnis Breakdown of academic impact, for papers by Alexander Stoff Breakdown of academic impact, for papers by Weibiao Huang Breakdown of academic impact, for papers by María Álvarez‐Viejo Breakdown of academic impact, for papers by Takehiko Yamazaki Breakdown of academic impact, for papers by Sophie Vériter Breakdown of academic impact, for papers by John M. Centanni Breakdown of academic impact, for papers by Ichiro Masaki Breakdown of academic impact, for papers by Li Deng Breakdown of academic impact, for papers by Joseph Michaels
Rankless by CCL
2026